Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2007Leukemia & lymphoma/Leukemia and lymphoma

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

RFRoland FenkDüsseldorf University HospitalMMMark MichaelDüsseldorf University HospitalFZFabian ZohrenMerus (Netherlands)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fenk et al. (2007) studied this question.

synapsesocial.com/papers/6a83732f3965fa42e1c94bf6https://doi.org/10.1080/10428190701694194
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION1998 · 1,527 citations
  2. 2Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines1996 · 155 citations
  3. 3Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma2004 · 817 citations
  4. 4PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma2005 · 319 citations